Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, non-randomized, open label study of ILX651 in patients with
hormone-refractory prostate cancer previously treated with docetaxel. Approximately 40
patients will be enrolled in this study that is expected to last 24 months. All patients will
be treated with ILX651 administered IV daily for 5 consecutive days every 21 days. The
primary objective of this study is to determine the PSA response rate. The secondary
objectives are to determine response of measurable disease, duration of response, time to PSA
progression, time to treatment failure, survival, safety and tolerability, and
pharmacokinetic profile of ILX651.